- Home
- JTAI vs SILO Comparison
JTAI vs SILO Comparison
Compare JTAI & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | SILO |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Apparel |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JTAI | SILO |
|---|---|---|
| Price | $0.13 | $0.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 50.9M | 103.7K |
| Earning Date | 03-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,584,279.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.13 | $0.27 |
| 52 Week High | $11.77 | $1.57 |
Technical Indicators
Market Signals| Indicator | JTAI | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 24.65 | 35.36 |
| Support Level | $0.13 | $0.29 |
| Resistance Level | $0.17 | $0.33 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 4.45 | 19.14 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.